Literature DB >> 15504828

Antipneumococcal activities of two novel macrolides, GW 773546 and GW 708408, compared with those of erythromycin, azithromycin, clarithromycin, clindamycin, and telithromycin.

Vlatka Matic1, Klaudia Kosowska, Bulent Bozdogan, Linda M Kelly, Kathy Smith, Lois M Ednie, Gengrong Lin, Kim L Credito, Catherine L Clark, Pamela McGhee, Glenn A Pankuch, Michael R Jacobs, Peter C Appelbaum.   

Abstract

The MICs of GW 773546, GW 708408, and telithromycin for 164 macrolide-susceptible and 161 macrolide-resistant pneumococci were low. The MICs of GW 773546, GW 708408, and telithromycin for macrolide-resistant strains were similar, irrespective of the resistance genotypes of the strains. Clindamycin was active against all macrolide-resistant strains except those with erm(B) and one strain with a 23S rRNA mutation. GW 773546, GW 708408, and telithromycin at two times their MICs were bactericidal after 24 h for 7 to 8 of 12 strains. Serial passages of 12 strains in the presence of sub-MICs yielded 54 mutants, 29 of which had changes in the L4 or L22 protein or the 23S rRNA sequence. Among the macrolide-susceptible strains, resistant mutants developed most rapidly after passage in the presence of clindamycin, GW 773546, erythromycin, azithromycin, and clarithromycin and slowest after passage in the presence of GW 708408 and telithromycin. Selection of strains for which MICs were >/=0.5 microg/ml from susceptible parents occurred only with erythromycin, azithromycin, clarithromycin, and clindamycin; 36 resistant clones from susceptible parent strains had changes in the sequences of the L4 or L22 protein or 23S rRNA. No mef(E) strains yielded resistant clones after passage in the presence of erythromycin and azithromycin. Selection with GW 773546, GW 708408, telithromycin, and clindamycin in two mef(E) strains did not raise the erythromycin, azithromycin, and clarithromycin MICs more than twofold. There were no change in the ribosomal protein (L4 or L22) or 23S rRNA sequences for 15 of 18 mutants selected for macrolide resistance; 3 mutants had changes in the L22-protein sequence. GW 773546, GW 708408, and telithromycin selected clones for which MICs were 0.03 to >2.0 microg/ml. Single-step studies showed mutation frequencies <5.0 x 10(-10) to 3.5 x 10(-7) for GW 773546, GW 708408, and telithromycin for macrolide-susceptible strains and 1.1 x 10(-7) to >4.3 x 10(-3) for resistant strains. The postantibiotic effects of GW 773546, GW 708408, and telithromycin were 2.4 to 9.8 h.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15504828      PMCID: PMC525431          DOI: 10.1128/AAC.48.11.4103-4112.2004

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  32 in total

Review 1.  Treatment and diagnosis of infections caused by drug-resistant Streptococcus pneumoniae.

Authors:  M R Jacobs
Journal:  Clin Infect Dis       Date:  1992-07       Impact factor: 9.079

2.  Geographic distribution of penicillin-resistant clones of Streptococcus pneumoniae: characterization by penicillin-binding protein profile, surface protein A typing, and multilocus enzyme analysis.

Authors:  R Munoz; J M Musser; M Crain; D E Briles; A Marton; A J Parkinson; U Sorensen; A Tomasz
Journal:  Clin Infect Dis       Date:  1992-07       Impact factor: 9.079

3.  Diversity of ribosomal mutations conferring resistance to macrolides, clindamycin, streptogramin, and telithromycin in Streptococcus pneumoniae.

Authors:  Annie Canu; Brigitte Malbruny; Maëlle Coquemont; Todd A Davies; Peter C Appelbaum; Roland Leclercq
Journal:  Antimicrob Agents Chemother       Date:  2002-01       Impact factor: 5.191

4.  In vitro selection of resistance to clinafloxacin, ciprofloxacin, and trovafloxacin in Streptococcus pneumoniae.

Authors:  K Nagai; T A Davies; G A Pankuch; B E Dewasse; M R Jacobs; P C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2000-10       Impact factor: 5.191

5.  Susceptibilities of Streptococcus pneumoniae and Haemophilus influenzae to 10 oral antimicrobial agents based on pharmacodynamic parameters: 1997 U.S. Surveillance study.

Authors:  M R Jacobs; S Bajaksouzian; A Zilles; G Lin; G A Pankuch; P C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  1999-08       Impact factor: 5.191

6.  Streptococcus pneumoniae in the USA: in vitro susceptibility and pharmacodynamic analysis.

Authors:  E O Mason; L B Lamberth; N L Kershaw; B L Prosser; A Zoe; P G Ambrose
Journal:  J Antimicrob Chemother       Date:  2000-05       Impact factor: 5.790

7.  Telithromycin post-antibiotic and post-antibiotic sub-MIC effects for 10 Gram-positive cocci.

Authors:  Michael R Jacobs; Saralee Bajaksouzian; Peter C Appelbaum
Journal:  J Antimicrob Chemother       Date:  2003-09-30       Impact factor: 5.790

8.  In vitro selection of resistance to four beta-lactams and azithromycin in Streptococcus pneumoniae.

Authors:  G A Pankuch; S A Jueneman; T A Davies; M R Jacobs; P C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  1998-11       Impact factor: 5.191

9.  Antibacterial resistance in Streptococcus pneumoniae and Haemophilus influenzae from Italy and Spain: data from the PROTEKT surveillance study, 1999-2000.

Authors:  A M Schito; G C Schito; E Debbia; G Russo; J Liñares; E Cercenado; E Bouza
Journal:  J Chemother       Date:  2003-06       Impact factor: 1.714

10.  Antimicrobial susceptibility of community-acquired respiratory tract pathogens in North America in 1999-2000: findings of the PROTEKT surveillance study.

Authors:  Daryl Hoban; Ken Waites; David Felmingham
Journal:  Diagn Microbiol Infect Dis       Date:  2003-04       Impact factor: 2.803

View more
  7 in total

1.  CEM-101 activity against Gram-positive organisms.

Authors:  Leah N Woosley; Mariana Castanheira; Ronald N Jones
Journal:  Antimicrob Agents Chemother       Date:  2010-02-22       Impact factor: 5.191

2.  Multistep resistance selection and postantibiotic-effect studies of the antipneumococcal activity of LBM415 compared to other agents.

Authors:  Klaudia Kosowska-Shick; Kim L Credito; Glenn A Pankuch; Bonifacio DeWasse; Pamela McGhee; Peter C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2006-11-20       Impact factor: 5.191

3.  Antipneumococcal activity of DW-224a, a new quinolone, compared to those of eight other agents.

Authors:  Klaudia Kosowska-Shick; Kim Credito; Glenn A Pankuch; Gengrong Lin; Bülent Bozdogan; Pamela McGhee; Bonifacio Dewasse; Dong-Rack Choi; Jei Man Ryu; Peter C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2006-06       Impact factor: 5.191

4.  Multistep resistance development studies of ceftaroline in gram-positive and -negative bacteria.

Authors:  Catherine Clark; Pamela McGhee; Peter C Appelbaum; Klaudia Kosowska-Shick
Journal:  Antimicrob Agents Chemother       Date:  2011-02-22       Impact factor: 5.191

Review 5.  Azithromycin extended release: a review of its use in the treatment of acute bacterial sinusitis and community-acquired pneumonia in the US.

Authors:  Tracy Swainston Harrison; Susan J Keam
Journal:  Drugs       Date:  2007       Impact factor: 9.546

6.  Recombineering reveals a diverse collection of ribosomal proteins L4 and L22 that confer resistance to macrolide antibiotics.

Authors:  Elie J Diner; Christopher S Hayes
Journal:  J Mol Biol       Date:  2009-01-03       Impact factor: 5.469

7.  In vitro capability of faropenem to select for resistant mutants of Streptococcus pneumoniae and Haemophilus influenzae.

Authors:  Klaudia Kosowska-Shick; Catherine Clark; Kim Credito; Bonifacio Dewasse; Linda Beachel; Lois Ednie; Peter C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2007-12-17       Impact factor: 5.191

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.